| 殷雪瑞,肖晋昌,李园园,等.经导管动脉化疗栓塞术联合安罗替尼及派安普利单抗治疗中晚期肝细胞癌的临床疗效和安全性分析[J].安徽医药,2025,29(11):2232-2236. |
| 经导管动脉化疗栓塞术联合安罗替尼及派安普利单抗治疗中晚期肝细胞癌的临床疗效和安全性分析 |
| Clinical efficacy and safety analysis of transcatheter arterial chemoembolization combined with anlotinib and penpulimab in the treatment of intermediate and advanced hepatocellular carcinoma |
| |
| DOI：10.3969/j.issn.1009-6469.2025.11.024 |
| 中文关键词: 癌，肝细胞 经导管动脉化疗栓塞术 系统治疗 安罗替尼 派安普利单抗 |
| 英文关键词: Carcinoma, hepatocellular Transcatheter arterial chemoembolization Systemic therapy Anlotinib Penpulimab |
| 基金项目: |
|
| 摘要点击次数: 504 |
| 全文下载次数: 172 |
| 中文摘要: |
| 目的评价经导管动脉化疗栓塞术( TACE)联合系统治疗(安罗替尼联合派安普利单抗)对中晚期肝细胞癌(HCC)的疗效和安全性。方法回顾性分析 2021年 9月至 2023年 6月徐州医科大学附属医院收治的 87例中晚期 HCC病人，观察组接受 TACE联合系统治疗，对照组进行 TACE治疗。治疗后每 1~3个月采用上腹部增强 CT或磁共振成像( MRI)进行随访。采用改良实体瘤疗效评价标准评价短期疗效，分析两组客观缓解率( ORR)、疾病控制率( DCR)、无进展生存期( PFS)和总生存期( OS)的差异，分析预后因素，并记录不良反应。结果观察组 47例，对照组 40例，两组在年龄、性别等基线资料上差异无统计学意义( P>0.05)。观察组和对照组病人的 ORR分别为 57.4%和 32.5%，DCR分别为 87.2%和 67.5%，中位 PFS分别为 11.8个月和7.7个月，中位 OS分别为 20.3个月和 11.3个月，均差异有统计学意义(均 P<0.05)。多因素分析显示，甲胎蛋白水平和治疗方式是影响病人预后的独立危险因素。观察组常见的不良反应为高血压( 59.6%)、乏力( 51.1%)，对照组常见的不良反应为发热(42.5%)、乏力( 37.5%)。观察组药物相关不良反应如蛋白尿、高血压、甲状腺功能减退症、手足综合征发生率高于对照组( P<0.05)，对症处理后均好转，其余不良反应均差异无统计学意义( P>0.05)。结论 TACE联合安罗替尼及派安普利单抗治疗中晚期 HCC是有效且安全的。 |
| 英文摘要: |
| Objective To evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with system-ic therapy (anlotinib plus penpulimab) in patients with intermediate and advanced hepatocellular carcinoma (HCC).Methods A retro-spective analysis was conducted on 87 patients with intermediate and advanced HCC admitted to the Affiliated Hospital of XuzhouMedical University from September 2021 to June 2023. The observation group received TACE combined with systemic therapy, and thecontrol group received TACE alone. After treatment, follow-up was performed every 1-3 months using enhanced upper abdominal CT or magnetic resonance imaging (MRI). Short-term efficacy was assessed using the modified response evaluation criteria in solid tumors,and the differences in objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival(OS) between the two groups were analyzed. Prognostic factors were analyzed, and adverse reactions were recorded.Results The obser-vation group included 47 patients and the control group 40 patients. There were no statistically significant difference in baseline charac-teristics such as age and gender between the two groups (P>0.05). The ORR in the observation and control groups was 57.4% and32.5%, respectively, the DCR was 87.2% and 67.5%, the median PFS was 11.8 months and 7.7 months, and the median OS was 20.3months and 11.3 months, respectively, with all differences being statistically significant (all P<0.05). Multifactorial analysis showed that the level of alpha-fetoprotein and treatment modality were independent risk factorsaffecting patient prognosis. Common adverse re-actions in the observation group were hypertension (59.6%) and malaise (51.1%), while in the control group they were fever (42.5%)and malaise (37.5%). The incidence of drug-related adverse reactions such as proteinuria, hypertension, hypothyroidism, and hand-foot syndrome was higher in the observation group than that in the control group (P<0.05). These reactions improved after symptomatic man-agement, and there were no statistically significant differences in the remaining adverse reactions (P<0.05).Conclusion TACE com-bined with anlotinib and penpulimab is effective and safe for the treatment of intermediate and advanced HCC. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
